{"page_content": "68\nReconciliation of GAAP to Non-GAAP Measures (In millions) (Unaudited)\n2018 2020 2016 2017 2019 2015 2014\nYears Ended December 31,\nData Notes\ni) The adjustments related primarily to noncash amortization \nof intangible assets from business acquisitions. For \nthe years ended December 31, 2020, 2019, 2018 and \n2017, the adjustments to operating income also included \nimpairments of intangible assets acquired in business \ncombinations.  \nii) The adjustments related to headcount charges, such \nas severance, and to asset charges, such as asset \nimpairments, accelerated depreciation and other charges \nrelated to the closure of our facilities. \niii) The adjustment related to the recognition of an additional \nyear of the non-tax deductible branded prescription drug \nfee, as required by final regulations issued by the Internal \nRevenue Service.\niv) For the year ended December 31, 2020, the adjustments \nrelated to the amortization of the basis difference from our \nBeiGene equity method investment, partially offset by a \ngain from legal judgment proceeds. For the year ended \nDecember 31, 2018, the adjustment related to the net \ngain associated with the Kirin-Amgen, Inc. acquisition. \nFor the year ended December 31, 2013, the adjustment \nincluded bridge financing costs associated with the Onyx \nbusiness combination.\nv) The tax effect of the adjustments between our GAAP and \nnon-GAAP results takes into account the tax treatment \nand related tax rate(s) that apply to each adjustment in \nthe applicable tax jurisdiction(s). Generally, this results \nin a tax impact at the U.S. marginal tax rate for certain \nadjustments, including the majority of amortization \nof intangible assets, whereas the tax impact of other \nadjustments, including restructuring expense, depends \non whether the amounts are deductible in the respective \ntax jurisdictions and the applicable tax rate(s) in those \njurisdictions.\nvi) The adjustments related to certain acquisition items and \nprior-period items excluded from GAAP earnings. For the \nyear ended December 31, 2017, the adjustment related \nprimarily to the impact of U.S. Corporate tax reform, \nincluding the repatriation tax on accumulated foreign \nearnings and the remeasurement of certain net deferred \nand other tax liabilities.2013\n $ 4,207 $ 4,116 $ 3,737 $ 3,562 $ 3,840 $ 4,070 $ 4,297 $ 4,083 \n \n  (120)   (87)   (78)   (77)   (78)   (89)   (124)   (142)\n  (2)   (2)   (2)   (3)   (7)   (64)   (49)   - \n  -    -    -    -    -    -    (3)   (12)\n  (122)   (89)   (80)   (80)   (85)   (153)   (176)   (154)\n $ 4,085 $ 4,027 $ 3,657 $ 3,482 $ 3,755 $ 3,917 $ 4,121 $ 3,929 \n               \n $ 9,139 $ 9,674 $ 10,263 $ 9,973 $ 9,794 $ 8,470 $ 6,191 $ 5,867 \n  3,013    1,438    1,557    1,594    1,510    1,377    1,546    986 \n  (3)   45    12    88    37    114    596    71 \n  185    -    -    -    105    91    (3)   14 \n  -    -    -    -    -    -    16    34 \n  -    -    -    -    129    - \n  -    -    25    3    -    -    -    - \n  3,195    1,483    1,594    1,685    1,652    1,582    2,284    1,105 \n $ 12,334 $ 11,157 $ 11,857 $ 11,658 $ 11,446 $ 10,052  $ 8,475 $ 6,972 \n               \n $ 7,264 $ 7,842 $ 8,394 $ 1,979 $ 7,722 $ 6,939 $ 5,158 $ 5,081 \n  3,195    1,483    1,594    1,685    1,652    1,582    2,284    1,105 \n  37    -    (68)   -    -    -    -    34 \n  (634)   (329)   (362)   (538)   (525)   (496)   (717)   (376)\n  (67)   32    15    6,120    (64)   (71)   (25)   (30)\n  2,531    1,186    1,179    7,267    1,063    1,015    1,542    733 \n $ 9,795 $ 9,028 $ 9,573 $ 9,246 $ 8,785 $ 7,954 $ 6,700 $ 5,814 \n               GAAP research and development expenses\nAdjustments to research and development expenses:\nAcquisition-related expenses (i)\nCertain charges pursuant to our restructuring and other cost savings initiatives (ii)\nStock option expense\nTotal adjustments to research and development expenses\nNon-GAAP research and development expenses \n \nGAAP operating income\nAdjustments to operating income:\nAcquisition-related expenses (i)\nCertain charges pursuant to our restructuring and other cost savings initiatives (ii)\nExpense (benefit) related to various legal proceedings\nStock option expense\nExpense resulting from clarified guidance on branded prescription drug fee (iii)\nOther\nTotal adjustments to operating income\nNon-GAAP operating income\nGAAP net income\nAdjustments to net income:\nAdjustments to operating income\nAdjustments to other income (iv)\nIncome tax effect of the above adjustments (v)\nOther income tax adjustments (vi)\nTotal adjustments to net income\nNon-GAAP net incomeAPPENDIX INTRODUCTION GOVERNANCECOVID- 19 \nRESPONSEBUSINESS \nETHICSETHICAL \nRESEARCHACCESS TO \nMEDICINEDIVERSITY, INCLUSION, \nAND BELONGINGENVIRONMENTAL\nSUSTAINABILITYRESPONSIBLE \nSOURCINGCOMMUNITY \nINVESTMENT", "metadata": {"source": "NASDAQ_AMGN_2020.pdf", "page": 67, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}